SecBot SecBot
SECBOTREPLAY Home › Report › XENE

XENE · Xenon Pharmaceuticals filed a definitive proxy statement for its 2025…

Xenon Pharmaceuticals Inc. · DEFA14A filed Apr 22, 2026 at 16:04 ET

At the news

NEUTRALIMPACT 2/10

DEFA14A filed Apr 22, 2026 at 16:04 ET

Xenon Pharmaceuticals filed a definitive proxy statement for its 2025 annual meeting, proposing the re-election of eight directors, approval of executive compensation, and reappointment of its auditor. This routine filing follows a recent amendment to its equity incentive plan, indicating ongoing governance activities.

  • Filing is a definitive proxy statement (DEFA14A) for the 2025 annual meeting
  • Proposes re-election of eight directors including Dawn Svoronos, Gillian Cannon, and Justin Gover
  • Seeks approval of executive compensation and reappointment of PwC as auditor
  • Follows recent 8-K filing amending the equity incentive plan

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access